

Global Peptide Vaccine Market Research Report 2023

<https://marketpublishers.com/r/G98E26560F1CEN.html>

Date: December 2023

Pages: 105

Price: US\$ 2,900.00 (Single User License)

ID: G98E26560F1CEN

Abstracts

Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.

According to QYResearch's new survey, global Peptide Vaccine market is projected to reach US\$ 4935.8 million in 2029, increasing from US\$ 3683 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Peptide Vaccine market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management,

further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Peptide Vaccine market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

By Company

Anergis

Antigen Express

Apitope Technology

Artificial Cell Technologies

Benovus Bio

Celgene Corporation

Immatics biotechnologies

Merck

ImmunoCellular Therapeutics

ISA Pharmaceuticals

Lytix Biopharma

Spotlight Innovation

OncoTherapy Science

Peptech

Pharmasyn tez

Sumitomo Dainippon Pharma

TapImmune

Targovax

Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Segment by Application

Prostate Cancer

Breast Cancer

Gastric Cancer

Lung Cancer

Pancreatic Cancer

Others

Consumption by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

The Peptide Vaccine report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Manufacturers' Competition Patterns

Chapter 3: Country Level Sales Analysis

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6: Manufacturers' Outline

Chapter 7: Industry Chain, Market Channel and Customer Analysis

Chapter 8: Market Opportunities and Challenges

Chapter 9: Market Conclusions

Chapter 10: Research Methodology and Data Source

Contents

1 PEPTIDE VACCINE MARKET OVERVIEW

- 1.1 Product Overview and Scope of Peptide Vaccine
- 1.2 Peptide Vaccine Segment by Type
 - 1.2.1 Global Peptide Vaccine Market Value Comparison by Type (2023-2029)
 - 1.2.2 Solution Phase Synthesis (SPS)
 - 1.2.3 Solid Phase Peptide Synthesis (SPPS)
- 1.3 Peptide Vaccine Segment by Application
 - 1.3.1 Global Peptide Vaccine Market Value by Application: (2023-2029)
 - 1.3.2 Prostate Cancer
 - 1.3.3 Breast Cancer
 - 1.3.4 Gastric Cancer
 - 1.3.5 Lung Cancer
 - 1.3.6 Pancreatic Cancer
 - 1.3.7 Others
- 1.4 Global Peptide Vaccine Market Size Estimates and Forecasts
 - 1.4.1 Global Peptide Vaccine Revenue 2018-2029
 - 1.4.2 Global Peptide Vaccine Sales 2018-2029
 - 1.4.3 Global Peptide Vaccine Market Average Price (2018-2029)
- 1.5 Assumptions and Limitations

2 PEPTIDE VACCINE MARKET COMPETITION BY MANUFACTURERS

- 2.1 Global Peptide Vaccine Sales Market Share by Manufacturers (2018-2023)
- 2.2 Global Peptide Vaccine Revenue Market Share by Manufacturers (2018-2023)
- 2.3 Global Peptide Vaccine Average Price by Manufacturers (2018-2023)
- 2.4 Global Peptide Vaccine Industry Ranking 2021 VS 2022 VS 2023
- 2.5 Global Key Manufacturers of Peptide Vaccine, Manufacturing Sites & Headquarters
- 2.6 Global Key Manufacturers of Peptide Vaccine, Product Type & Application
- 2.7 Peptide Vaccine Market Competitive Situation and Trends
 - 2.7.1 Peptide Vaccine Market Concentration Rate
 - 2.7.2 The Global Top 5 and Top 10 Largest Peptide Vaccine Players Market Share by Revenue
 - 2.7.3 Global Peptide Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 PEPTIDE VACCINE RETROSPECTIVE MARKET SCENARIO BY REGION

3.1 Global Peptide Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Peptide Vaccine Global Peptide Vaccine Sales by Region: 2018-2029

3.2.1 Global Peptide Vaccine Sales by Region: 2018-2023

3.2.2 Global Peptide Vaccine Sales by Region: 2024-2029

3.3 Global Peptide Vaccine Global Peptide Vaccine Revenue by Region: 2018-2029

3.3.1 Global Peptide Vaccine Revenue by Region: 2018-2023

3.3.2 Global Peptide Vaccine Revenue by Region: 2024-2029

3.4 North America Peptide Vaccine Market Facts & Figures by Country

3.4.1 North America Peptide Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Peptide Vaccine Sales by Country (2018-2029)

3.4.3 North America Peptide Vaccine Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Peptide Vaccine Market Facts & Figures by Country

3.5.1 Europe Peptide Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Peptide Vaccine Sales by Country (2018-2029)

3.5.3 Europe Peptide Vaccine Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Peptide Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Peptide Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Peptide Vaccine Sales by Country (2018-2029)

3.6.3 Asia Pacific Peptide Vaccine Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Peptide Vaccine Market Facts & Figures by Country

3.7.1 Latin America Peptide Vaccine Market Size by Country: 2018 VS 2022 VS 2029

- 3.7.2 Latin America Peptide Vaccine Sales by Country (2018-2029)
- 3.7.3 Latin America Peptide Vaccine Revenue by Country (2018-2029)

- 3.7.4 Mexico

- 3.7.5 Brazil

- 3.7.6 Argentina

3.8 Middle East and Africa Peptide Vaccine Market Facts & Figures by Country

- 3.8.1 Middle East and Africa Peptide Vaccine Market Size by Country: 2018 VS 2022 VS 2029

- 3.8.2 Middle East and Africa Peptide Vaccine Sales by Country (2018-2029)

- 3.8.3 Middle East and Africa Peptide Vaccine Revenue by Country (2018-2029)

- 3.8.4 Turkey

- 3.8.5 Saudi Arabia

- 3.8.6 UAE

4 SEGMENT BY TYPE

- 4.1 Global Peptide Vaccine Sales by Type (2018-2029)

- 4.1.1 Global Peptide Vaccine Sales by Type (2018-2023)

- 4.1.2 Global Peptide Vaccine Sales by Type (2024-2029)

- 4.1.3 Global Peptide Vaccine Sales Market Share by Type (2018-2029)

- 4.2 Global Peptide Vaccine Revenue by Type (2018-2029)

- 4.2.1 Global Peptide Vaccine Revenue by Type (2018-2023)

- 4.2.2 Global Peptide Vaccine Revenue by Type (2024-2029)

- 4.2.3 Global Peptide Vaccine Revenue Market Share by Type (2018-2029)

- 4.3 Global Peptide Vaccine Price by Type (2018-2029)

5 SEGMENT BY APPLICATION

- 5.1 Global Peptide Vaccine Sales by Application (2018-2029)

- 5.1.1 Global Peptide Vaccine Sales by Application (2018-2023)

- 5.1.2 Global Peptide Vaccine Sales by Application (2024-2029)

- 5.1.3 Global Peptide Vaccine Sales Market Share by Application (2018-2029)

- 5.2 Global Peptide Vaccine Revenue by Application (2018-2029)

- 5.2.1 Global Peptide Vaccine Revenue by Application (2018-2023)

- 5.2.2 Global Peptide Vaccine Revenue by Application (2024-2029)

- 5.2.3 Global Peptide Vaccine Revenue Market Share by Application (2018-2029)

- 5.3 Global Peptide Vaccine Price by Application (2018-2029)

6 KEY COMPANIES PROFILED

6.1 Anergis

- 6.1.1 Anergis Corporation Information
- 6.1.2 Anergis Description and Business Overview
- 6.1.3 Anergis Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.1.4 Anergis Peptide Vaccine Product Portfolio
- 6.1.5 Anergis Recent Developments/Updates

6.2 Antigen Express

- 6.2.1 Antigen Express Corporation Information
- 6.2.2 Antigen Express Description and Business Overview
- 6.2.3 Antigen Express Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.2.4 Antigen Express Peptide Vaccine Product Portfolio
- 6.2.5 Antigen Express Recent Developments/Updates

6.3 Apitope Technology

- 6.3.1 Apitope Technology Corporation Information
- 6.3.2 Apitope Technology Description and Business Overview
- 6.3.3 Apitope Technology Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.3.4 Apitope Technology Peptide Vaccine Product Portfolio
- 6.3.5 Apitope Technology Recent Developments/Updates

6.4 Artificial Cell Technologies

- 6.4.1 Artificial Cell Technologies Corporation Information
- 6.4.2 Artificial Cell Technologies Description and Business Overview
- 6.4.3 Artificial Cell Technologies Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.4.4 Artificial Cell Technologies Peptide Vaccine Product Portfolio
- 6.4.5 Artificial Cell Technologies Recent Developments/Updates

6.5 Benovus Bio

- 6.5.1 Benovus Bio Corporation Information
- 6.5.2 Benovus Bio Description and Business Overview
- 6.5.3 Benovus Bio Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.5.4 Benovus Bio Peptide Vaccine Product Portfolio
- 6.5.5 Benovus Bio Recent Developments/Updates

6.6 Celgene Corporation

- 6.6.1 Celgene Corporation Corporation Information
- 6.6.2 Celgene Corporation Description and Business Overview
- 6.6.3 Celgene Corporation Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)

- 6.6.4 Celgene Corporation Peptide Vaccine Product Portfolio
- 6.6.5 Celgene Corporation Recent Developments/Updates
- 6.7 Immatics biotechnologies
 - 6.6.1 Immatics biotechnologies Corporation Information
 - 6.6.2 Immatics biotechnologies Description and Business Overview
 - 6.6.3 Immatics biotechnologies Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.4.4 Immatics biotechnologies Peptide Vaccine Product Portfolio
 - 6.7.5 Immatics biotechnologies Recent Developments/Updates
- 6.8 Merck
 - 6.8.1 Merck Corporation Information
 - 6.8.2 Merck Description and Business Overview
 - 6.8.3 Merck Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.8.4 Merck Peptide Vaccine Product Portfolio
 - 6.8.5 Merck Recent Developments/Updates
- 6.9 ImmunoCellular Therapeutics
 - 6.9.1 ImmunoCellular Therapeutics Corporation Information
 - 6.9.2 ImmunoCellular Therapeutics Description and Business Overview
 - 6.9.3 ImmunoCellular Therapeutics Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.9.4 ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio
 - 6.9.5 ImmunoCellular Therapeutics Recent Developments/Updates
- 6.10 ISA Pharmaceuticals
 - 6.10.1 ISA Pharmaceuticals Corporation Information
 - 6.10.2 ISA Pharmaceuticals Description and Business Overview
 - 6.10.3 ISA Pharmaceuticals Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.10.4 ISA Pharmaceuticals Peptide Vaccine Product Portfolio
 - 6.10.5 ISA Pharmaceuticals Recent Developments/Updates
- 6.11 Lytix Biopharma
 - 6.11.1 Lytix Biopharma Corporation Information
 - 6.11.2 Lytix Biopharma Peptide Vaccine Description and Business Overview
 - 6.11.3 Lytix Biopharma Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.11.4 Lytix Biopharma Peptide Vaccine Product Portfolio
 - 6.11.5 Lytix Biopharma Recent Developments/Updates
- 6.12 Spotlight Innovation
 - 6.12.1 Spotlight Innovation Corporation Information
 - 6.12.2 Spotlight Innovation Peptide Vaccine Description and Business Overview

- 6.12.3 Spotlight Innovation Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.12.4 Spotlight Innovation Peptide Vaccine Product Portfolio
- 6.12.5 Spotlight Innovation Recent Developments/Updates
- 6.13 OncoTherapy Science
 - 6.13.1 OncoTherapy Science Corporation Information
 - 6.13.2 OncoTherapy Science Peptide Vaccine Description and Business Overview
 - 6.13.3 OncoTherapy Science Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.13.4 OncoTherapy Science Peptide Vaccine Product Portfolio
 - 6.13.5 OncoTherapy Science Recent Developments/Updates
- 6.14 Peptech
 - 6.14.1 Peptech Corporation Information
 - 6.14.2 Peptech Peptide Vaccine Description and Business Overview
 - 6.14.3 Peptech Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.14.4 Peptech Peptide Vaccine Product Portfolio
 - 6.14.5 Peptech Recent Developments/Updates
- 6.15 Pharmasyn tez
 - 6.15.1 Pharmasyn tez Corporation Information
 - 6.15.2 Pharmasyn tez Peptide Vaccine Description and Business Overview
 - 6.15.3 Pharmasyn tez Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.15.4 Pharmasyn tez Peptide Vaccine Product Portfolio
 - 6.15.5 Pharmasyn tez Recent Developments/Updates
- 6.16 Sumitomo Dainippon Pharma
 - 6.16.1 Sumitomo Dainippon Pharma Corporation Information
 - 6.16.2 Sumitomo Dainippon Pharma Peptide Vaccine Description and Business Overview
 - 6.16.3 Sumitomo Dainippon Pharma Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.16.4 Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio
 - 6.16.5 Sumitomo Dainippon Pharma Recent Developments/Updates
- 6.17 TapImmune
 - 6.17.1 TapImmune Corporation Information
 - 6.17.2 TapImmune Peptide Vaccine Description and Business Overview
 - 6.17.3 TapImmune Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
 - 6.17.4 TapImmune Peptide Vaccine Product Portfolio
 - 6.17.5 TapImmune Recent Developments/Updates
- 6.18 Targovax
 - 6.18.1 Targovax Corporation Information

- 6.18.2 Targovax Peptide Vaccine Description and Business Overview
- 6.18.3 Targovax Peptide Vaccine Sales, Revenue and Gross Margin (2018-2023)
- 6.18.4 Targovax Peptide Vaccine Product Portfolio
- 6.18.5 Targovax Recent Developments/Updates

7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS

- 7.1 Peptide Vaccine Industry Chain Analysis
- 7.2 Peptide Vaccine Key Raw Materials
 - 7.2.1 Key Raw Materials
 - 7.2.2 Raw Materials Key Suppliers
- 7.3 Peptide Vaccine Production Mode & Process
- 7.4 Peptide Vaccine Sales and Marketing
 - 7.4.1 Peptide Vaccine Sales Channels
 - 7.4.2 Peptide Vaccine Distributors
- 7.5 Peptide Vaccine Customers

8 PEPTIDE VACCINE MARKET DYNAMICS

- 8.1 Peptide Vaccine Industry Trends
- 8.2 Peptide Vaccine Market Drivers
- 8.3 Peptide Vaccine Market Challenges
- 8.4 Peptide Vaccine Market Restraints

9 RESEARCH FINDING AND CONCLUSION

10 METHODOLOGY AND DATA SOURCE

- 10.1 Methodology/Research Approach
 - 10.1.1 Research Programs/Design
 - 10.1.2 Market Size Estimation
 - 10.1.3 Market Breakdown and Data Triangulation
- 10.2 Data Source
 - 10.2.1 Secondary Sources
 - 10.2.2 Primary Sources
- 10.3 Author List
- 10.4 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Peptide Vaccine Market Value Comparison by Type (2023-2029) & (US\$ Million)

Table 2. Global Peptide Vaccine Market Value Comparison by Application (2023-2029) & (US\$ Million)

Table 3. Global Peptide Vaccine Market Competitive Situation by Manufacturers in 2022

Table 4. Global Peptide Vaccine Sales (K Dose) of Key Manufacturers (2018-2023)

Table 5. Global Peptide Vaccine Sales Market Share by Manufacturers (2018-2023)

Table 6. Global Peptide Vaccine Revenue (US\$ Million) by Manufacturers (2018-2023)

Table 7. Global Peptide Vaccine Revenue Share by Manufacturers (2018-2023)

Table 8. Global Market Peptide Vaccine Average Price (US\$/Dose) of Key Manufacturers (2018-2023)

Table 9. Global Key Players of Peptide Vaccine, Industry Ranking, 2021 VS 2022 VS 2023

Table 10. Global Key Manufacturers of Peptide Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Peptide Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Peptide Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Peptide Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Vaccine as of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Peptide Vaccine Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 17. Global Peptide Vaccine Sales by Region (2018-2023) & (K Dose)

Table 18. Global Peptide Vaccine Sales Market Share by Region (2018-2023)

Table 19. Global Peptide Vaccine Sales by Region (2024-2029) & (K Dose)

Table 20. Global Peptide Vaccine Sales Market Share by Region (2024-2029)

Table 21. Global Peptide Vaccine Revenue by Region (2018-2023) & (US\$ Million)

Table 22. Global Peptide Vaccine Revenue Market Share by Region (2018-2023)

Table 23. Global Peptide Vaccine Revenue by Region (2024-2029) & (US\$ Million)

Table 24. Global Peptide Vaccine Revenue Market Share by Region (2024-2029)

Table 25. North America Peptide Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 26. North America Peptide Vaccine Sales by Country (2018-2023) & (K Dose)

Table 27. North America Peptide Vaccine Sales by Country (2024-2029) & (K Dose)

Table 28. North America Peptide Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 29. North America Peptide Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 30. Europe Peptide Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. Europe Peptide Vaccine Sales by Country (2018-2023) & (K Dose)

Table 32. Europe Peptide Vaccine Sales by Country (2024-2029) & (K Dose)

Table 33. Europe Peptide Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 34. Europe Peptide Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 35. Asia Pacific Peptide Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US\$ Million)

Table 36. Asia Pacific Peptide Vaccine Sales by Region (2018-2023) & (K Dose)

Table 37. Asia Pacific Peptide Vaccine Sales by Region (2024-2029) & (K Dose)

Table 38. Asia Pacific Peptide Vaccine Revenue by Region (2018-2023) & (US\$ Million)

Table 39. Asia Pacific Peptide Vaccine Revenue by Region (2024-2029) & (US\$ Million)

Table 40. Latin America Peptide Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 41. Latin America Peptide Vaccine Sales by Country (2018-2023) & (K Dose)

Table 42. Latin America Peptide Vaccine Sales by Country (2024-2029) & (K Dose)

Table 43. Latin America Peptide Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 44. Latin America Peptide Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Peptide Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 46. Middle East & Africa Peptide Vaccine Sales by Country (2018-2023) & (K Dose)

Table 47. Middle East & Africa Peptide Vaccine Sales by Country (2024-2029) & (K Dose)

Table 48. Middle East & Africa Peptide Vaccine Revenue by Country (2018-2023) & (US\$ Million)

Table 49. Middle East & Africa Peptide Vaccine Revenue by Country (2024-2029) & (US\$ Million)

Table 50. Global Peptide Vaccine Sales (K Dose) by Type (2018-2023)

Table 51. Global Peptide Vaccine Sales (K Dose) by Type (2024-2029)

Table 52. Global Peptide Vaccine Sales Market Share by Type (2018-2023)

Table 53. Global Peptide Vaccine Sales Market Share by Type (2024-2029)

Table 54. Global Peptide Vaccine Revenue (US\$ Million) by Type (2018-2023)

- Table 55. Global Peptide Vaccine Revenue (US\$ Million) by Type (2024-2029)
- Table 56. Global Peptide Vaccine Revenue Market Share by Type (2018-2023)
- Table 57. Global Peptide Vaccine Revenue Market Share by Type (2024-2029)
- Table 58. Global Peptide Vaccine Price (US\$/Dose) by Type (2018-2023)
- Table 59. Global Peptide Vaccine Price (US\$/Dose) by Type (2024-2029)
- Table 60. Global Peptide Vaccine Sales (K Dose) by Application (2018-2023)
- Table 61. Global Peptide Vaccine Sales (K Dose) by Application (2024-2029)
- Table 62. Global Peptide Vaccine Sales Market Share by Application (2018-2023)
- Table 63. Global Peptide Vaccine Sales Market Share by Application (2024-2029)
- Table 64. Global Peptide Vaccine Revenue (US\$ Million) by Application (2018-2023)
- Table 65. Global Peptide Vaccine Revenue (US\$ Million) by Application (2024-2029)
- Table 66. Global Peptide Vaccine Revenue Market Share by Application (2018-2023)
- Table 67. Global Peptide Vaccine Revenue Market Share by Application (2024-2029)
- Table 68. Global Peptide Vaccine Price (US\$/Dose) by Application (2018-2023)
- Table 69. Global Peptide Vaccine Price (US\$/Dose) by Application (2024-2029)
- Table 70. Anergis Corporation Information
- Table 71. Anergis Description and Business Overview
- Table 72. Anergis Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 73. Anergis Peptide Vaccine Product
- Table 74. Anergis Recent Developments/Updates
- Table 75. Antigen Express Corporation Information
- Table 76. Antigen Express Description and Business Overview
- Table 77. Antigen Express Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 78. Antigen Express Peptide Vaccine Product
- Table 79. Antigen Express Recent Developments/Updates
- Table 80. Apitope Technology Corporation Information
- Table 81. Apitope Technology Description and Business Overview
- Table 82. Apitope Technology Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 83. Apitope Technology Peptide Vaccine Product
- Table 84. Apitope Technology Recent Developments/Updates
- Table 85. Artificial Cell Technologies Corporation Information
- Table 86. Artificial Cell Technologies Description and Business Overview
- Table 87. Artificial Cell Technologies Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 88. Artificial Cell Technologies Peptide Vaccine Product
- Table 89. Artificial Cell Technologies Recent Developments/Updates

- Table 90. Benovus Bio Corporation Information
- Table 91. Benovus Bio Description and Business Overview
- Table 92. Benovus Bio Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 93. Benovus Bio Peptide Vaccine Product
- Table 94. Benovus Bio Recent Developments/Updates
- Table 95. Celgene Corporation Corporation Information
- Table 96. Celgene Corporation Description and Business Overview
- Table 97. Celgene Corporation Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 98. Celgene Corporation Peptide Vaccine Product
- Table 99. Celgene Corporation Recent Developments/Updates
- Table 100. Immatics biotechnologies Corporation Information
- Table 101. Immatics biotechnologies Description and Business Overview
- Table 102. Immatics biotechnologies Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 103. Immatics biotechnologies Peptide Vaccine Product
- Table 104. Immatics biotechnologies Recent Developments/Updates
- Table 105. Merck Corporation Information
- Table 106. Merck Description and Business Overview
- Table 107. Merck Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 108. Merck Peptide Vaccine Product
- Table 109. Merck Recent Developments/Updates
- Table 110. ImmunoCellular Therapeutics Corporation Information
- Table 111. ImmunoCellular Therapeutics Description and Business Overview
- Table 112. ImmunoCellular Therapeutics Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 113. ImmunoCellular Therapeutics Peptide Vaccine Product
- Table 114. ImmunoCellular Therapeutics Recent Developments/Updates
- Table 115. ISA Pharmaceuticals Corporation Information
- Table 116. ISA Pharmaceuticals Description and Business Overview
- Table 117. ISA Pharmaceuticals Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)
- Table 118. ISA Pharmaceuticals Peptide Vaccine Product
- Table 119. ISA Pharmaceuticals Recent Developments/Updates
- Table 120. Lytix Biopharma Corporation Information
- Table 121. Lytix Biopharma Description and Business Overview
- Table 122. Lytix Biopharma Peptide Vaccine Sales (K Dose), Revenue (US\$ Million),

Price (US\$/Dose) and Gross Margin (2018-2023)

Table 123. Lytix Biopharma Peptide Vaccine Product

Table 124. Lytix Biopharma Recent Developments/Updates

Table 125. Spotlight Innovation Corporation Information

Table 126. Spotlight Innovation Description and Business Overview

Table 127. Spotlight Innovation Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 128. Spotlight Innovation Peptide Vaccine Product

Table 129. Spotlight Innovation Recent Developments/Updates

Table 130. OncoTherapy Science Corporation Information

Table 131. OncoTherapy Science Description and Business Overview

Table 132. OncoTherapy Science Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 133. OncoTherapy Science Peptide Vaccine Product

Table 134. OncoTherapy Science Recent Developments/Updates

Table 135. Peptech Corporation Information

Table 136. Peptech Description and Business Overview

Table 137. Peptech Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 138. Peptech Peptide Vaccine Product

Table 139. Peptech Recent Developments/Updates

Table 140. Pharmasyn tez Corporation Information

Table 141. Pharmasyn tez Description and Business Overview

Table 142. Pharmasyn tez Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 143. Pharmasyn tez Peptide Vaccine Product

Table 144. Pharmasyn tez Recent Developments/Updates

Table 145. Sumitomo Dainippon Pharma Corporation Information

Table 146. Sumitomo Dainippon Pharma Description and Business Overview

Table 147. Sumitomo Dainippon Pharma Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 148. Sumitomo Dainippon Pharma Peptide Vaccine Product

Table 149. Sumitomo Dainippon Pharma Recent Developments/Updates

Table 150. TapImmune Corporation Information

Table 151. TapImmune Description and Business Overview

Table 152. TapImmune Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 153. TapImmune Peptide Vaccine Product

Table 154. TapImmune Recent Developments/Updates

Table 155. Targovax Corporation Information

Table 156. Targovax Description and Business Overview

Table 157. Targovax Peptide Vaccine Sales (K Dose), Revenue (US\$ Million), Price (US\$/Dose) and Gross Margin (2018-2023)

Table 158. Targovax Peptide Vaccine Product

Table 159. Targovax Recent Developments/Updates

Table 160. Key Raw Materials Lists

Table 161. Raw Materials Key Suppliers Lists

Table 162. Peptide Vaccine Distributors List

Table 163. Peptide Vaccine Customers List

Table 164. Peptide Vaccine Market Trends

Table 165. Peptide Vaccine Market Drivers

Table 166. Peptide Vaccine Market Challenges

Table 167. Peptide Vaccine Market Restraints

Table 168. Research Programs/Design for This Report

Table 169. Key Data Information from Secondary Sources

Table 170. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Peptide Vaccine

Figure 2. Global Peptide Vaccine Market Value Comparison by Type (2023-2029) & (US\$ Million)

Figure 3. Global Peptide Vaccine Market Share by Type in 2022 & 2029

Figure 4. Solution Phase Synthesis (SPS) Product Picture

Figure 5. Solid Phase Peptide Synthesis (SPPS) Product Picture

Figure 6. Global Peptide Vaccine Market Value Comparison by Application (2023-2029) & (US\$ Million)

Figure 7. Global Peptide Vaccine Market Share by Application in 2022 & 2029

Figure 8. Prostate Cancer

Figure 9. Breast Cancer

Figure 10. Gastric Cancer

Figure 11. Lung Cancer

Figure 12. Pancreatic Cancer

Figure 13. Others

Figure 14. Global Peptide Vaccine Revenue, (US\$ Million), 2018 VS 2022 VS 2029

Figure 15. Global Peptide Vaccine Market Size (2018-2029) & (US\$ Million)

Figure 16. Global Peptide Vaccine Sales (2018-2029) & (K Dose)

Figure 17. Global Peptide Vaccine Average Price (US\$/Dose) & (2018-2029)

Figure 18. Peptide Vaccine Report Years Considered

Figure 19. Peptide Vaccine Sales Share by Manufacturers in 2022

Figure 20. Global Peptide Vaccine Revenue Share by Manufacturers in 2022

Figure 21. The Global 5 and 10 Largest Peptide Vaccine Players: Market Share by Revenue in 2022

Figure 22. Peptide Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 23. Global Peptide Vaccine Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Figure 24. North America Peptide Vaccine Sales Market Share by Country (2018-2029)

Figure 25. North America Peptide Vaccine Revenue Market Share by Country (2018-2029)

Figure 26. United States Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 27. Canada Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 28. Europe Peptide Vaccine Sales Market Share by Country (2018-2029)

Figure 29. Europe Peptide Vaccine Revenue Market Share by Country (2018-2029)

Figure 30. Germany Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 31. France Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 32. U.K. Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 33. Italy Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 34. Russia Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 35. Asia Pacific Peptide Vaccine Sales Market Share by Region (2018-2029)

Figure 36. Asia Pacific Peptide Vaccine Revenue Market Share by Region (2018-2029)

Figure 37. China Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 38. Japan Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 39. South Korea Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 40. India Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 41. Australia Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 42. China Taiwan Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 43. Indonesia Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 44. Thailand Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 45. Malaysia Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 46. Latin America Peptide Vaccine Sales Market Share by Country (2018-2029)

Figure 47. Latin America Peptide Vaccine Revenue Market Share by Country (2018-2029)

Figure 48. Mexico Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 49. Brazil Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 50. Argentina Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 51. Middle East & Africa Peptide Vaccine Sales Market Share by Country (2018-2029)

Figure 52. Middle East & Africa Peptide Vaccine Revenue Market Share by Country (2018-2029)

Figure 53. Turkey Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 54. Saudi Arabia Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 55. UAE Peptide Vaccine Revenue Growth Rate (2018-2029) & (US\$ Million)

Figure 56. Global Sales Market Share of Peptide Vaccine by Type (2018-2029)

Figure 57. Global Revenue Market Share of Peptide Vaccine by Type (2018-2029)

Figure 58. Global Peptide Vaccine Price (US\$/Dose) by Type (2018-2029)

Figure 59. Global Sales Market Share of Peptide Vaccine by Application (2018-2029)

Figure 60. Global Revenue Market Share of Peptide Vaccine by Application (2018-2029)

Figure 61. Global Peptide Vaccine Price (US\$/Dose) by Application (2018-2029)

Figure 62. Peptide Vaccine Value Chain

Figure 63. Peptide Vaccine Production Process

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Distributors Profiles

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

I would like to order

Product name: Global Peptide Vaccine Market Research Report 2023

Product link: <https://marketpublishers.com/r/G98E26560F1CEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G98E26560F1CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970